AR115069A1 - Virus vacuna quimérico sintético - Google Patents
Virus vacuna quimérico sintéticoInfo
- Publication number
- AR115069A1 AR115069A1 ARP190101165A ARP190101165A AR115069A1 AR 115069 A1 AR115069 A1 AR 115069A1 AR P190101165 A ARP190101165 A AR P190101165A AR P190101165 A ARP190101165 A AR P190101165A AR 115069 A1 AR115069 A1 AR 115069A1
- Authority
- AR
- Argentina
- Prior art keywords
- synthetic
- chemeric
- vaccine virus
- synthetic chimeric
- viruses
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/91—Cell lines ; Processes using cell lines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862665973P | 2018-05-02 | 2018-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR115069A1 true AR115069A1 (es) | 2020-11-25 |
Family
ID=68386164
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190101165A AR115069A1 (es) | 2018-05-02 | 2019-05-02 | Virus vacuna quimérico sintético |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12529036B2 (enExample) |
| EP (1) | EP3788142A4 (enExample) |
| JP (3) | JP2021522784A (enExample) |
| CN (2) | CN112543806B (enExample) |
| AR (1) | AR115069A1 (enExample) |
| AU (1) | AU2019262149B2 (enExample) |
| BR (1) | BR112020022181A2 (enExample) |
| CA (1) | CA3099330A1 (enExample) |
| MX (1) | MX2020011586A (enExample) |
| SG (1) | SG11202010272PA (enExample) |
| TW (1) | TW201946651A (enExample) |
| WO (1) | WO2019213452A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3535389A4 (en) | 2016-11-02 | 2020-06-03 | David Evans | SYNTHETIC CHIMERIC POCKET VIRUS |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| SG11202010272PA (en) | 2018-05-02 | 2020-11-27 | David Evans | Synthetic chimeric vaccinia virus |
| MX2022009200A (es) * | 2020-02-03 | 2023-01-04 | Vectores a base de poxvirus producidos por acido desoxirribonucleico (adn) natural o sintetico y usos de los mismos. | |
| TWI902763B (zh) * | 2020-02-26 | 2025-11-01 | 加拿大亞伯大州立大學理事會 | 基於重組痘病毒之抗SARS-CoV-2病毒疫苗 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| PE20231175A1 (es) | 2020-11-19 | 2023-08-01 | Kalivir Immunotherapeutics Inc | Inmunoterapia oncolitica por remodelacion del microambiente tumoral |
| CA3206004A1 (en) | 2021-02-02 | 2022-08-11 | Mary Jo Hauser | Viral constructs for use in enhancing t-cell priming during vaccination |
| IL316712B2 (en) * | 2021-04-30 | 2025-12-01 | Kalivir Immunotherapeutics Inc | Oncolytic viruses for modified mhc expression |
| WO2023168286A1 (en) | 2022-03-01 | 2023-09-07 | Tonix Pharmaceuticals Holding Corp. | Recombinant poxvirus based vaccine against the omicron strain of sars-cov-2 virus and variants thereof |
| CN116042656A (zh) * | 2022-11-25 | 2023-05-02 | 中山大学附属第七医院(深圳) | 一种猴痘病毒mRNA疫苗及其制备方法与用途 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2787577A (en) | 1953-12-01 | 1957-04-02 | Lilly Co Eli | Stable smallpox vaccine |
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US6004777A (en) | 1997-03-12 | 1999-12-21 | Virogenetics Corporation | Vectors having enhanced expression, and methods of making and uses thereof |
| US6723325B1 (en) | 2001-04-23 | 2004-04-20 | Acambis, Inc. | Smallpox vaccine |
| US20040014034A1 (en) * | 2002-06-06 | 2004-01-22 | Evans David H | Method of producing a recombinant virus |
| AU2004269320B2 (en) | 2003-06-20 | 2009-12-24 | Protein Sciences Corporation | Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using |
| WO2005028634A2 (en) | 2003-09-18 | 2005-03-31 | Emory University | Improved mva vaccines |
| WO2005103259A1 (en) | 2004-04-26 | 2005-11-03 | University Health Network | Sars-cov nucleocapsid protein epitopes and uses thereof |
| JPWO2006022215A1 (ja) | 2004-08-23 | 2008-05-08 | 財団法人ヒューマンサイエンス振興財団 | ＳＡＲＳ−コロナウイルスタンパク質をコードするＤＮＡを保有する組換えワクチニアウイルスＤＩｓ株、およびその利用 |
| CN101020055B (zh) | 2006-02-16 | 2012-08-08 | 中国疾病预防控制中心性病艾滋病预防控制中心 | 基于复制型痘苗病毒载体的sars疫苗 |
| WO2008100292A2 (en) | 2006-10-16 | 2008-08-21 | Genelux Corporation | Modified vaccinia virus strains for use in diagnostic and therapeutic methods |
| WO2009117030A2 (en) | 2007-12-19 | 2009-09-24 | Macrogenics, Inc. | Improved compositions for the prevention and treatment of smallpox |
| CN114262690A (zh) * | 2011-04-15 | 2022-04-01 | 吉恩勒克斯公司 | 减毒的痘苗病毒的克隆毒株及其使用方法 |
| FI20115914A7 (fi) * | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| WO2014160475A1 (en) | 2013-03-13 | 2014-10-02 | Aboody Karen S | Tropic cell based virotherapy for the treatment of cancer |
| ES2768292T3 (es) | 2013-04-10 | 2020-06-22 | Tot Shanghai R&D Center Co Ltd | Cepas de virus vaccinia mutante, usos de estas y método para producirlas |
| EP3045181B1 (en) | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| EA201800148A1 (ru) | 2015-08-11 | 2019-01-31 | Калиди Биотерапьютикс, Инк. | Оспенная вакцина для лечения рака |
| JP2018533547A (ja) | 2015-09-16 | 2018-11-15 | 株式会社新日本科学 | ワクチン組成物 |
| WO2018057755A1 (en) | 2016-09-21 | 2018-03-29 | Thorne Stephen H | High mobility group box i mutant |
| EP3535389A4 (en) * | 2016-11-02 | 2020-06-03 | David Evans | SYNTHETIC CHIMERIC POCKET VIRUS |
| ES2702618B2 (es) | 2017-09-04 | 2019-10-31 | Inst De Salud Carlos Iii | Producto de combinación que comprende una célula madre mesenquimatosa modificada y una sustancia antigénica. |
| EP3787681A4 (en) * | 2018-05-02 | 2022-01-19 | Tonix Pharma Holdings Limited | Stem cells comprising synthetic chimeric vaccinia virus and methods of using them |
| SG11202010272PA (en) | 2018-05-02 | 2020-11-27 | David Evans | Synthetic chimeric vaccinia virus |
-
2019
- 2019-05-02 SG SG11202010272PA patent/SG11202010272PA/en unknown
- 2019-05-02 MX MX2020011586A patent/MX2020011586A/es unknown
- 2019-05-02 AU AU2019262149A patent/AU2019262149B2/en active Active
- 2019-05-02 EP EP19796145.1A patent/EP3788142A4/en active Pending
- 2019-05-02 JP JP2020560920A patent/JP2021522784A/ja not_active Withdrawn
- 2019-05-02 BR BR112020022181-3A patent/BR112020022181A2/pt unknown
- 2019-05-02 CN CN201980029677.9A patent/CN112543806B/zh active Active
- 2019-05-02 WO PCT/US2019/030486 patent/WO2019213452A1/en not_active Ceased
- 2019-05-02 CN CN202510639606.8A patent/CN121320271A/zh active Pending
- 2019-05-02 US US17/050,946 patent/US12529036B2/en active Active
- 2019-05-02 CA CA3099330A patent/CA3099330A1/en active Pending
- 2019-05-02 TW TW108115290A patent/TW201946651A/zh unknown
- 2019-05-02 AR ARP190101165A patent/AR115069A1/es unknown
-
2024
- 2024-02-28 JP JP2024028557A patent/JP2024051112A/ja active Pending
-
2025
- 2025-09-11 JP JP2025151400A patent/JP2025178289A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3788142A1 (en) | 2021-03-10 |
| TW201946651A (zh) | 2019-12-16 |
| EP3788142A4 (en) | 2022-04-27 |
| US20210230560A1 (en) | 2021-07-29 |
| US12529036B2 (en) | 2026-01-20 |
| BR112020022181A2 (pt) | 2021-02-09 |
| CA3099330A1 (en) | 2019-11-07 |
| AU2019262149B2 (en) | 2025-09-11 |
| WO2019213452A9 (en) | 2021-01-14 |
| CN121320271A (zh) | 2026-01-13 |
| AU2019262149A1 (en) | 2020-11-12 |
| JP2025178289A (ja) | 2025-12-05 |
| JP2021522784A (ja) | 2021-09-02 |
| JP2024051112A (ja) | 2024-04-10 |
| CN112543806B (zh) | 2025-06-06 |
| CN112543806A (zh) | 2021-03-23 |
| WO2019213452A1 (en) | 2019-11-07 |
| MX2020011586A (es) | 2020-12-07 |
| SG11202010272PA (en) | 2020-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011586A (es) | Virus vaccinia quimerico sintetico. | |
| MX2015007755A (es) | Vacunas contra virus de la influenza y sus usos. | |
| CL2018001051A1 (es) | Vacunas de ácido nucleico contra el virus varicela zoster (vzv) | |
| UY37563A (es) | Aislados de bacillus y usos de los mismos | |
| MX2021000193A (es) | Selección de epítopos de vacunas personalizadas contra el cáncer. | |
| MX383507B (es) | Antígenos del virus de la inmunodeficiencia humana, vectores, composiciones y métodos de uso de estos. | |
| CR20200460A (es) | Suministro intracelular de biomeléculas para modificar respuestas inmunes | |
| UY37564A (es) | Aislados de lysinibacillus y usos de los mismos | |
| MX2023000211A (es) | Composiciones de vacuna que tienen estabilidad e inmunogenicidad mejoradas. | |
| ZA202403393B (en) | Synthetic chimeric poxviruses | |
| AR133161A2 (es) | Vacunas de partículas tipo virus (vlp) contra el parvovirus canino (cpv) y sus usos | |
| MX2022002106A (es) | Formulaciones de vacuna de vial unico. | |
| MX2021010060A (es) | Produccion de virus en huevos aviares. | |
| ECSP18081582A (es) | Constructos de alfavirus vivo atenuado y métodos y usos de los mismos | |
| CR20140189S (es) | Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue | |
| MX2019007973A (es) | Composiciones universales de vacuna de la influenza. | |
| MX2016016746A (es) | Composiciones de vacuna con adyuvante dual, preparacion y usos. | |
| CO2017006958A2 (es) | Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para la preparación y uso de los mismos | |
| DOP2016000220A (es) | PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS. | |
| UY36394A (es) | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso. | |
| MX2017011322A (es) | Sistema de marcadores, en particular para antigenos subunitarios expresados por baculovirus. | |
| MX382530B (es) | Vacunas inactivadas contra la influenza canina, metodos para elaborarlas y sus usos. | |
| UY35418A (es) | Vacuna que proporciona protección frente a diferentes Picornavirus humanos. | |
| MX2020010410A (es) | Empaquetado de oligonucleotidos en particulas similares a virus. | |
| MX2022001430A (es) | Formulaciones de vacuna contra chikungu?a. |